RAC Regulatory Affairs Certification Exam — Questions and Answers

Question 1: Which tool is commonly used in strategic regulatory planning to assess likelihood and impact of regulatory risks?

Ishikawa (fishbone) diagram for quality defects
Risk matrix (probability × impact grid) (Correct answer)
GANTT chart
SWOT analysis of competitors

Correct answer: Risk matrix (probability × impact grid)

A risk matrix plots regulatory risks by probability and impact severity, enabling teams to prioritize mitigation efforts strategically.

Question 2: A sponsor submits an Investigational New Drug (IND) application for a Phase 1 study. The FDA issues a clinical hold 25 days after submission. Which of the following is the MOST likely reason for the clinical hold?

The Investigator's Brochure is found to be misleading or materially incomplete. (Correct answer)
The sponsor has not finalized the commercial manufacturing process.
The Phase 3 clinical trial protocol has not yet been submitted for review.
The proposed patient population is too small to achieve statistical significance.

Correct answer: The Investigator's Brochure is found to be misleading or materially incomplete.

According to FDA regulations (21 CFR 312.42), grounds for a clinical hold on a Phase 1 study include an Investigator's Brochure that is misleading, erroneous, or materially incomplete. Other primary reasons for a Phase 1 hold relate to unreasonable risk to subjects, unqualified investigators, or insufficient information to assess risk. Statistical power (A) is a concern for later phase studies, not typically Phase 1. Finalizing the commercial manufacturing process (C) is not required at the IND stage. The Phase 3 protocol (D) is not required for a Phase 1 study to commence.

Question 3: Which program allows FDA to expedite the development and review of drugs for serious conditions where preliminary evidence shows substantial improvement over available therapies?

Fast Track designation
Priority Review designation
Breakthrough Therapy designation (Correct answer)
Accelerated Approval pathway

Correct answer: Breakthrough Therapy designation

Breakthrough Therapy designation is intended to expedite development of drugs showing preliminary clinical evidence of substantial improvement over existing therapy for serious conditions.

Question 4: Under US GMP for pharmaceuticals (21 CFR Part 211), which of the following responsibilities and authorities is uniquely assigned to the Quality Control Unit (QCU)?

The final disposition (approval or rejection) of all drug product batches. (Correct answer)
Drafting and authoring all manufacturing Standard Operating Procedures (SOPs).
Executing the process validation protocols for new equipment.
Performing routine environmental monitoring of the manufacturing facility.

Correct answer: The final disposition (approval or rejection) of all drug product batches.

21 CFR 211.22 explicitly states that the Quality Control Unit shall have the responsibility and authority to approve or reject all components and drug products. While the QCU reviews and approves other documents and activities, the final authority to release or reject a batch rests solely with them.

Question 5: Which document outlines a company's regulatory submission strategy?

Regulatory strategy plan (Correct answer)
Manufacturing plan
Advertising budget
Clinical trial protocol

Correct answer: Regulatory strategy plan

A regulatory strategy plan is a comprehensive document that outlines the specific regulatory pathway, key milestones, timelines, and resources needed to bring a product to market and maintain its compliance throughout its lifecycle. It details how the company will navigate regulatory requirements, manage submissions, and interact with health authorities. This plan serves as a roadmap for all regulatory activities.

Question 6: What is the primary function of a Design History File (DHF) in the development of a medical device subject to 21 CFR Part 820?

It contains the records describing the design history of a finished device, demonstrating that the design was developed in accordance with the approved design plan (Correct answer)
It is FDA's internal review record generated during the 510(k) premarket review
It documents the clinical trial endpoints and protocol amendments for the device
It serves as the Device Master Record for manufacturing instructions

Correct answer: It contains the records describing the design history of a finished device, demonstrating that the design was developed in accordance with the approved design plan

The DHF compiles all design control records for a device, providing objective evidence that the design development process met requirements under 21 CFR 820.30.

Question 7: A sponsor's novel drug development program is on clinical hold due to safety concerns. The sponsor has submitted a complete response to the hold issues, but the agency and sponsor agree that the path forward is unclear. Which type of formal meeting with the FDA is most appropriate to request to resolve the impasse?

Type A Meeting (Correct answer)
Type C Meeting
Type B Meeting
Pre-IND Meeting

Correct answer: Type A Meeting

A Type A meeting is specifically designed for situations that are delaying the overall product development, such as resolving a clinical hold or addressing a dispute where the development program is stalled. Type B meetings are for pre-defined milestones (e.g., pre-NDA), and Type C meetings are for any other topic not covered by Type A or B. A Pre-IND meeting would have occurred before the IND was filed and the clinical hold was placed.

Question 8: In a GMP environment, which out-of-specification (OOS) investigation step must occur before retesting?

Phase I laboratory investigation (Correct answer)
Batch disposition decision
CAPA implementation
Regulatory notification

Correct answer: Phase I laboratory investigation

FDA's 2006 OOS guidance requires a Phase I laboratory investigation to assess analyst error and instrument performance before any retesting.

Question 9: A biosimilar regulatory strategy differs from a standard biologic strategy primarily because it requires:

A totality-of-evidence approach demonstrating no clinically meaningful differences from the reference product (Correct answer)
A full de novo clinical development program identical to the reference product
Only analytical characterization with no clinical data
Orphan drug designation to qualify for abbreviated pathways

Correct answer: A totality-of-evidence approach demonstrating no clinically meaningful differences from the reference product

Biosimilar approval relies on a totality-of-evidence approach showing no clinically meaningful differences from the reference product in terms of safety, purity, and potency.

Question 10: What is the strategic significance of the FDA's 505(b)(2) pathway compared to a full NDA?

It allows reliance on published literature or FDA's prior findings, reducing the data package needed (Correct answer)
It is only available for biologic products
It requires a completely novel active ingredient not previously approved
It eliminates the need for any clinical trials

Correct answer: It allows reliance on published literature or FDA's prior findings, reducing the data package needed

The 505(b)(2) pathway enables applicants to rely on existing FDA findings of safety and efficacy, significantly reducing development costs and timelines versus a full standalone NDA.

Question 11: A clinical trial investigator at a site becomes aware of a serious adverse event (SAE) that is both unexpected and fatal. According to FDA regulations (21 CFR 312.32), what is the sponsor's reporting obligation to the FDA?

The sponsor must report the event to the FDA within 30 calendar days.
The sponsor is only required to report the event in the annual safety report.
The sponsor must report the fatal, unexpected suspected adverse reaction to the FDA as soon as possible, but no later than 7 calendar days after the sponsor's initial receipt of the information. (Correct answer)
The sponsor must report the event to the FDA as soon as possible, but no later than 15 calendar days after initial receipt of the information.

Correct answer: The sponsor must report the fatal, unexpected suspected adverse reaction to the FDA as soon as possible, but no later than 7 calendar days after the sponsor's initial receipt of the information.

FDA regulations require expedited reporting for serious and unexpected suspected adverse reactions. For events that are fatal or life-threatening, the sponsor must notify the FDA within 7 calendar days. The 15-day timeline applies to other serious, unexpected suspected adverse reactions.

Question 12: When preparing the technical documentation for a medical device to be marketed in the European Union under the Medical Device Regulation (MDR - EU 2017/745), which of the following is a critical component required in Annex II?

A detailed description of the design and manufacturing processes. (Correct answer)
The curriculum vitae of the company's Chief Executive Officer.
A summary of all marketing and sales activities.
A copy of the company's annual financial report.

Correct answer: A detailed description of the design and manufacturing processes.

Annex II of the EU MDR outlines the required contents of the technical documentation. A key element is detailed information concerning the design and manufacture of the device. This includes drawings, specifications, and a description of the manufacturing methods and facilities to demonstrate conformity with the General Safety and Performance Requirements.

Question 13: Under 21 CFR Part 211, which document must be prepared and followed for each batch of drug product?

Batch production record (Correct answer)
Device history record
Design history file
Master batch record

Correct answer: Batch production record

21 CFR 211.188 requires a batch production record prepared for each batch as an accurate reproduction of the master production record.

Question 14: A key distinction between a regulatory STRATEGY and a regulatory PLAN is that a strategy:

is only created after a product has been rejected by a regulatory agency.
is a simple checklist of submission documents and their due dates.
focuses only on the post-market surveillance activities required for the product.
considers the entire product lifecycle and aligns regulatory activities with broader business objectives. (Correct answer)

Correct answer: considers the entire product lifecycle and aligns regulatory activities with broader business objectives.

A regulatory strategy is a comprehensive, high-level document that aligns regulatory activities with business goals over the entire product lifecycle. It is proactive and considers long-term objectives, such as target markets, competitive positioning, and lifecycle management. In contrast, a regulatory plan is more tactical, focusing on the specific tasks, timelines, and deliverables required to execute the strategy, such as a submission timeline.

Question 15: A company receives approval for a New Drug Application (NDA). Several years post-approval, the FDA requires the sponsor to conduct a new clinical trial to assess a newly identified serious risk associated with the drug's long-term use. This type of study is BEST described as a:

Phase 4 Clinical Trial
Postmarket Requirement (PMR) (Correct answer)
Investigator-Initiated Study
Post-Approval Commitment (PMC)

Correct answer: Postmarket Requirement (PMR)

A study that FDA requires a sponsor to conduct after a drug is approved is called a Postmarket Requirement (PMR). The Food and Drug Administration Amendments Act (FDAAA) of 2007 gave the FDA authority to require PMRs to assess known serious risks, signals of serious risk, or to identify unexpected serious risks. A Post-Approval Commitment (PMC) is a study the sponsor agrees to conduct but is not strictly required by law.

Question 16: Which metric is MOST useful for quantifying the real-world safety signal in post-market surveillance data?

Number of social media mentions
Gross revenue per product line
Complaint rate per units distributed (Correct answer)
Total units manufactured per quarter

Correct answer: Complaint rate per units distributed

Expressing complaints as a rate per units distributed normalizes the data, allowing meaningful comparison across time periods and product versions.

Question 17: A sponsor of an approved Class III medical device is required to submit post-approval reports to the FDA to ensure continued safety and effectiveness. Which of the following is a mandatory reporting requirement for the holder of an approved Premarket Approval (PMA) application?

Quarterly reports on sales and distribution data.
Periodic Medical Device Reports (MDRs) for adverse events and annual reports. (Correct answer)
Submitting a 510(k) for any manufacturing change.
A De Novo petition to confirm the device classification.

Correct answer: Periodic Medical Device Reports (MDRs) for adverse events and annual reports.

Holders of an approved PMA are subject to post-approval requirements, which include submitting Medical Device Reports (MDRs) for deaths, serious injuries, and certain malfunctions as per 21 CFR 803. They are also typically required to submit annual reports summarizing new safety and effectiveness information.

Question 18: A biotech company is developing a novel combination medical device for the US market. Early in the development process, the regulatory affairs professional recommends a pre-submission meeting with the FDA. What is the most significant strategic advantage of this early interaction?

To obtain early feedback and clarification on regulatory expectations, potentially avoiding costly delays later. (Correct answer)
To lobby the agency to change existing regulations to favor the new product.
To fulfill the mandatory first step required for all new device submissions.
To receive a guaranteed approval timeline from the regulatory agency.

Correct answer: To obtain early feedback and clarification on regulatory expectations, potentially avoiding costly delays later.

Engaging with regulatory authorities early in the development process is a critical strategic activity. The main benefit is gaining clarity on regulatory expectations, which helps in designing studies and preparing submissions that meet the agency's requirements. This proactive approach can prevent significant delays and resource expenditure that might arise from misunderstandings discovered late in the process. It does not guarantee approval timelines and is not always a mandatory first step, nor is its purpose to lobby for regulatory change.

Question 19: A medical device company is preparing a premarket submission for a new Class II diagnostic device. The device has the same intended use and similar technological characteristics as a legally marketed device (a predicate device). Which type of submission is MOST appropriate to seek marketing authorization in the United States?

Investigational Device Exemption (IDE)
De Novo Classification Request
Premarket Approval (PMA)
Premarket Notification (510(k)) (Correct answer)

Correct answer: Premarket Notification (510(k))

A Premarket Notification (510(k)) is the appropriate submission pathway for a device that is substantially equivalent to a legally marketed predicate device. This pathway is used for most Class II devices and some Class I devices. The submission's purpose is to demonstrate that the new device is as safe and effective as the predicate.

Question 20: A regulatory team is using RACI charting during submission planning. What does the 'A' (Accountable) role signify?

The person who performs the actual task
The person who is ultimately answerable for the correct and thorough completion of the task (Correct answer)
The person consulted for technical expertise
All stakeholders who receive task updates

Correct answer: The person who is ultimately answerable for the correct and thorough completion of the task

In a RACI chart, 'Accountable' designates the individual who owns the outcome and is answerable if the task is not completed correctly, typically only one per task.

Question 21: A medical device manufacturer discovers a recurring nonconformity during in-process testing of a Class II device. According to 21 CFR 820.100, which of the following is the MOST appropriate initial step in the Corrective and Preventive Action (CAPA) process?

Immediately scrapping all affected lots of the device.
Implementing a production-wide change to the manufacturing process.
Analyzing all relevant quality data to identify the root cause of the nonconformity. (Correct answer)
Disseminating information about the quality problem to all production staff.

Correct answer: Analyzing all relevant quality data to identify the root cause of the nonconformity.

According to 21 CFR 820.100(a), the CAPA process requires manufacturers to establish procedures for analyzing various sources of quality data to identify existing and potential causes of nonconforming product. Investigating the cause of the nonconformity is a critical first step before implementing any corrective actions, ensuring that the action taken is effective and appropriate.

Question 22: A pharmaceutical company is developing a novel drug-eluting stent, a product combining a drug and a device. To formulate an effective regulatory strategy in the United States, what is the MOST critical initial step?

Developing separate marketing applications for the drug and device components to streamline the review process.
Submitting a Request for Designation (RFD) to the Office of Combination Products (OCP) to determine the product's Primary Mode of Action (PMOA). (Correct answer)
Engaging a contract manufacturing organization that is compliant with both 21 CFR 211 and 21 CFR 820.
Beginning clinical trials immediately to gather efficacy data for both the drug and device components.

Correct answer: Submitting a Request for Designation (RFD) to the Office of Combination Products (OCP) to determine the product's Primary Mode of Action (PMOA).

For a combination product like a drug-eluting stent, the most critical first step in regulatory strategy is to determine the Primary Mode of Action (PMOA). The PMOA dictates which FDA center (CDER, CBER, or CDRH) will have primary review jurisdiction. The Office of Combination Products (OCP) is responsible for this assignment. If the PMOA is unclear, a sponsor should submit a Request for Designation (RFD) to the OCP for a formal determination, which is fundamental to defining the entire regulatory pathway.

Question 23: When creating a strategic regulatory plan, the process of gathering and analyzing publicly available information on competitor products, regulatory agency decisions, and new guidance documents is known as:

Clinical trial monitoring
Marketing research
Regulatory intelligence (Correct answer)
Post-market surveillance

Correct answer: Regulatory intelligence

Regulatory intelligence is the process of gathering and analyzing publicly available regulatory, scientific, and legal information to inform a company's regulatory strategy. This activity helps a company understand the current regulatory landscape, anticipate changes, learn from competitors' experiences, and make more informed strategic decisions throughout the product lifecycle.

Question 24: When preparing a briefing package for a Pre-Submission (Q-Sub) meeting with the FDA for a new medical device, which of the following is the MOST critical component to include?

Detailed financial projections for the first five years.
Specific, forward-looking questions for the agency on which feedback is sought. (Correct answer)
A complete list of all anticipated marketing claims.
The final, locked-down version of the device's Instructions for Use (IFU).

Correct answer: Specific, forward-looking questions for the agency on which feedback is sought.

The primary purpose of a Q-Submission is to obtain feedback from the agency to guide product development and submission preparation. Therefore, including clear, specific, and well-reasoned questions is the most critical component, as these questions will frame the entire discussion and the feedback provided by the FDA. The other elements, while potentially part of the overall package, are secondary to the core goal of getting answers to specific regulatory, technical, or clinical questions.

Question 25: What is the purpose of the ICH guidelines?

Local drug pricing regulation
Standardize preclinical animal testing only
Healthcare facility inspections
International harmonization of drug regulations (Correct answer)

Correct answer: International harmonization of drug regulations

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) brings together regulatory authorities and the pharmaceutical industry from various regions. Its purpose is to achieve greater harmonization in the interpretation and application of technical guidelines and requirements for drug registration. This reduces duplication of testing and speeds up the availability of new medicines globally.

Question 26: What is a key feature of effective regulatory communication?

Clear, accurate, and timely dialogue (Correct answer)
Communicating only after rejection
Relying solely on emails
Using technical jargon

Correct answer: Clear, accurate, and timely dialogue

Effective regulatory communication is characterized by clear, accurate, and timely dialogue with regulatory authorities. This approach fosters transparency, builds trust, and facilitates efficient review processes. Proactive and precise communication helps address questions promptly, clarify complex issues, and avoid misunderstandings that could lead to delays or rejections.

Question 27: A clinical investigator is preparing for a new industry-sponsored drug trial. By signing the Form FDA 1572, the investigator is making a legally binding commitment to the sponsor to perform which of the following actions?

Guarantee a specific number of subjects will be enrolled at their site.
Secure marketing approval for the investigational product upon study completion.
Personally conduct all study-related procedures and assessments.
Ensure the study is conducted according to the protocol and personally supervise the overall conduct of the trial. (Correct answer)

Correct answer: Ensure the study is conducted according to the protocol and personally supervise the overall conduct of the trial.

The Form FDA 1572 is a Statement of Investigator, which serves as a signed agreement between the investigator and the sponsor. By signing it, the investigator commits to follow FDA regulations for conducting a clinical investigation. This includes personally conducting or supervising the study, ensuring it follows the approved protocol, and protecting the rights, safety, and welfare of subjects. It does not guarantee enrollment numbers (A), require the investigator to perform every single task without delegation (B), or involve them in the marketing approval process (D).

Question 28: Which tool is most useful for proactively identifying regulatory risks before a product submission?

SWOT analysis applied to regulatory activities
A Gantt chart of submission milestones
FMEA (Failure Mode and Effects Analysis) of the regulatory strategy (Correct answer)
Post-market surveillance data review

Correct answer: FMEA (Failure Mode and Effects Analysis) of the regulatory strategy

FMEA applied to regulatory strategy systematically identifies potential failure modes in the regulatory plan and their impact on approval timelines.

Question 29: When interacting with the EMA, what is the role of a Rapporteur and Co-Rapporteur?

They serve as legal representatives for the applicant
They manage post-market surveillance programs
They are CHMP members assigned to lead assessment of a marketing authorization application (Correct answer)
They conduct GMP inspections at manufacturing sites

Correct answer: They are CHMP members assigned to lead assessment of a marketing authorization application

The Rapporteur and Co-Rapporteur are CHMP members from EU member states assigned to perform the primary scientific assessment of a centralized marketing authorization application.

Question 30: Which of the following BEST describes the role of a Target Product Profile (TPP) in regulatory strategic planning?

It is primarily a marketing document used to secure funding from investors and has minimal impact on regulatory interactions.
It is a dynamic, strategic tool that outlines the desired product characteristics to guide development and facilitate alignment with regulatory authorities. (Correct answer)
It is a legally binding contract submitted to regulatory authorities outlining the final, unchangeable product specifications.
It is a static document created at the end of the development process to summarize the product's final characteristics for labeling.

Correct answer: It is a dynamic, strategic tool that outlines the desired product characteristics to guide development and facilitate alignment with regulatory authorities.

A Target Product Profile (TPP) is a strategic planning tool that outlines the desired characteristics of a product. It is intended to be a 'living document' that evolves as new data becomes available. Its purpose is to guide internal development decisions and facilitate productive discussions with regulatory authorities, ensuring that the development program is aligned with regulatory expectations and clinical needs from an early stage.

Question 31: A medical device manufacturer has developed a novel device for diagnosing a rare neurological condition. There is no legally marketed predicate device available. The device presents a low-to-moderate risk profile. Which of the following premarket submission pathways is the most appropriate for this device?

Premarket Notification (510(k))
Premarket Approval (PMA)
Humanitarian Device Exemption (HDE)
De Novo Classification Request (Correct answer)

Correct answer: De Novo Classification Request

The De Novo pathway is designed for novel, low-to-moderate risk devices for which there is no existing predicate device. This process allows the FDA to classify the new device as Class I or II, making it a predicate for future submissions. A 510(k) is not possible without a predicate. A PMA is for high-risk (Class III) devices. An HDE is for devices that treat or diagnose conditions affecting a very small number of patients per year, and while this might apply, the De Novo pathway is the primary route for novel, lower-risk devices seeking classification.

Question 32: What distinguishes a Post-Market Surveillance Report (PMSR) from a Periodic Safety Update Report (PSUR) under EU MDR?

Both are required for all device classes regardless of risk
PMSRs and PSURs are interchangeable terms under EU MDR
PMSRs are for Class I devices only; PSURs are required for Class IIa, IIb, and III (Correct answer)
PSURs are for Class I devices; PMSRs apply to higher-risk classes

Correct answer: PMSRs are for Class I devices only; PSURs are required for Class IIa, IIb, and III

Under EU MDR Articles 85 and 86, Class I devices need a PMSR while Class IIa, IIb, and III devices require the more comprehensive PSUR.

Question 33: What is the purpose of a Special Protocol Assessment (SPA) agreement between a sponsor and FDA for a Phase III trial?

To allow expedited enrollment without informed consent
To waive IRB review requirements
To grant automatic Breakthrough Therapy designation
To secure FDA agreement that the protocol design is acceptable to support a future NDA/BLA (Correct answer)

Correct answer: To secure FDA agreement that the protocol design is acceptable to support a future NDA/BLA

An SPA provides sponsors with FDA's binding agreement that the protocol design, endpoints, and statistical analysis plan are acceptable for regulatory approval.

Question 34: A pharmaceutical company holds an approved New Drug Application (NDA). Which of the following is considered an "unexpected" adverse drug experience that would require an expedited 15-day "Alert Report" to the FDA?

A serious adverse event that is already well-documented in the Investigator's Brochure from the clinical trial phase.
An adverse event that is listed in the current product labeling, but is now occurring with greater severity. (Correct answer)
A non-serious adverse event observed for the first time in a postmarketing study.
A mild headache, which is listed as a common side effect in the product's core safety information.

Correct answer: An adverse event that is listed in the current product labeling, but is now occurring with greater severity.

Per 21 CFR 314.80(a), an "unexpected" adverse drug experience is one not listed in the current labeling. The definition explicitly includes events that may be related to an event in the labeling but differ because of greater severity or specificity. The Investigator's Brochure is not the same as the approved labeling, and non-serious or expected events do not trigger the 15-day reporting requirement.

Question 35: An Institutional Review Board (IRB) is reviewing a protocol for a Phase 3 clinical trial. According to ICH GCP, which of the following is the PRIMARY responsibility of the IRB?

Verifying the accuracy of the data collected at the clinical sites.
Confirming the sponsor has adequate financial resources to complete the study.
Protecting the rights, safety, and well-being of the human subjects participating in the trial. (Correct answer)
Ensuring the scientific validity and statistical robustness of the trial design.

Correct answer: Protecting the rights, safety, and well-being of the human subjects participating in the trial.

The fundamental purpose of an IRB is to protect the rights and welfare of human research subjects. While scientific design is reviewed to assess the risk/benefit ratio, the IRB's primary mandate is the ethical oversight and protection of participants, not statistical validation, data verification, or financial auditing.

Question 36: In a pharmacokinetics bridging study supporting a new pediatric formulation, which parameter is most critical to demonstrate bioequivalence to the adult reference product?

Tmax
Renal clearance rate
Volume of distribution at steady state
AUC and Cmax within the 80–125% confidence interval limits (Correct answer)

Correct answer: AUC and Cmax within the 80–125% confidence interval limits

FDA bioequivalence standards require the 90% CI for AUC and Cmax ratios to fall within 80–125% of the reference product.

Question 37: Which phase of clinical development is specifically designed to evaluate dose-response relationships and identify the dose regimen for Phase III confirmatory trials?

Phase I
Phase II (Correct answer)
Phase IV
Phase III

Correct answer: Phase II

Phase II trials evaluate therapeutic activity, dose-response, and identify an optimal dose and regimen to carry forward into pivotal Phase III studies.

Question 38: A company is planning to market a new cardiac stent, a life-sustaining device that will be permanently implanted. This type of device is considered high-risk (Class III). Which submission pathway to the FDA will be required?

Investigational Device Exemption (IDE)
De Novo Classification Request
Premarket Notification (510(k))
Premarket Approval (PMA) (Correct answer)

Correct answer: Premarket Approval (PMA)

Premarket Approval (PMA) is the most stringent regulatory pathway and is required for Class III devices, which are high-risk devices that are life-sustaining, life-supporting, or present a potential unreasonable risk of illness or injury. A cardiac stent falls into this category. The PMA process requires a demonstration of the device's safety and effectiveness through extensive scientific, preclinical, and clinical data.

Question 39: In EU regulatory strategy, the primary purpose of a Scientific Advice procedure with EMA is:

To negotiate pricing and reimbursement terms
To replace the CHMP review process for urgent products
To gain EMA guidance on data requirements before a marketing authorization application (Correct answer)
To obtain binding commitments on approval timelines

Correct answer: To gain EMA guidance on data requirements before a marketing authorization application

EMA Scientific Advice provides non-binding guidance on the data package and study designs needed to support a future marketing authorization application.

Question 40: Under FDA's Accelerated Approval pathway, what is required after a product receives accelerated approval?

The sponsor must refile a complete NDA within 6 months
The sponsor must conduct post-approval confirmatory trials to verify clinical benefit (Correct answer)
The sponsor may market the product without further obligations
The product automatically converts to full approval after 2 years

Correct answer: The sponsor must conduct post-approval confirmatory trials to verify clinical benefit

Accelerated Approval requires sponsors to conduct post-approval confirmatory trials verifying clinical benefit; FDA can withdraw approval if the trials fail to confirm the benefit.

Question 41: Which U.S. law established the FDA’s authority to oversee drug safety?

Food, Drug, and Cosmetic Act (Correct answer)
Kefauver-Harris Amendment
Prescription Drug Marketing Act
Drug Listing Act

Correct answer: Food, Drug, and Cosmetic Act

The Federal Food, Drug, and Cosmetic (FD&C) Act, passed in 1938, is the foundational law that granted the FDA its authority to regulate drugs, food, and cosmetics. It mandated that new drugs be proven safe before marketing and established requirements for labeling. While subsequent amendments like Kefauver-Harris added efficacy requirements, the FD&C Act initially established the FDA's core oversight of drug safety.

Question 42: In the context of PMS complaint handling, what does 'MDR decisioning' require the manufacturer to document?

Marketing strategy changes resulting from the complaint
The number of social media reposts of the complaint
The customer's satisfaction score after complaint resolution
The rationale for why a complaint does or does not meet MDR reporting criteria (Correct answer)

Correct answer: The rationale for why a complaint does or does not meet MDR reporting criteria

FDA expects written documentation of the analysis and justification used to determine whether each complaint meets MDR reportability thresholds.

Question 43: When developing a regulatory strategy for a combination product in the US, which FDA center typically takes lead jurisdiction?

The center chosen by the sponsor
The center with the most expertise in the primary mode of action (Correct answer)
Always CDER regardless of device component
Always CDRH regardless of drug component

Correct answer: The center with the most expertise in the primary mode of action

FDA assigns lead jurisdiction to the center whose regulation is most appropriate based on the primary mode of action of the combination product.

Question 44: Under EU regulations, which procedure allows a company to obtain a single marketing authorization valid across all EU member states?

National Authorization Procedure
Centralized Procedure (Correct answer)
Mutual Recognition Procedure
Decentralized Procedure

Correct answer: Centralized Procedure

The Centralized Procedure, managed by EMA and CHMP, results in a single EU-wide marketing authorization valid in all EU member states plus EEA countries.

Question 45: What must a sponsor do if FDA issues a Complete Response Letter (CRL) for an NDA?

Respond to all deficiencies identified or request a meeting to discuss them (Correct answer)
Withdraw the application immediately
Automatically receive approval after 6 months
Resubmit a new NDA from scratch

Correct answer: Respond to all deficiencies identified or request a meeting to discuss them

A CRL informs sponsors of deficiencies; the sponsor must address all issues and resubmit or may request a meeting with FDA to discuss the deficiencies.

Question 46: Which document establishes the formal agreement between a sponsor and a CRO, transferring specific IND obligations?

Quality Agreement
Master Service Agreement (MSA)
Written transfer agreement per 21 CFR 312.52 (Correct answer)
Clinical Trial Agreement (CTA)

Correct answer: Written transfer agreement per 21 CFR 312.52

21 CFR 312.52 requires a written agreement specifying which IND obligations have been transferred from sponsor to CRO.

Question 47: A regulatory team is evaluating whether to seek Breakthrough Therapy Designation. What is the key eligibility criterion?

The drug must treat a rare disease affecting fewer than 200,000 patients
Preliminary clinical evidence must show substantial improvement over available therapies for a serious condition (Correct answer)
The product must already have FDA Fast Track status
Phase 3 trials must be completed with positive results

Correct answer: Preliminary clinical evidence must show substantial improvement over available therapies for a serious condition

Breakthrough Therapy Designation requires preliminary clinical evidence showing substantial improvement on a clinically meaningful endpoint over existing therapies for a serious condition.

Question 48: A company is planning a regulatory strategy for a digital health product incorporating AI/ML. The most relevant FDA regulatory framework to consider is:

The OTC monograph pathway for software products
21 CFR Part 820 Quality System Regulation only
FDA's action plan for AI/ML-based Software as a Medical Device (SaMD) (Correct answer)
The traditional PMA pathway without modification

Correct answer: FDA's action plan for AI/ML-based Software as a Medical Device (SaMD)

FDA's AI/ML-based SaMD action plan and the predetermined change control plan framework are specifically designed for adaptive AI/ML technologies in medical devices.

Question 49: A company is planning global market entry for a Class II medical device. Which regulatory pathway typically offers the fastest US market access?

Humanitarian Device Exemption
De Novo classification
PMA
510(k) with predicate (Correct answer)

Correct answer: 510(k) with predicate

A 510(k) submission demonstrating substantial equivalence to a legally marketed predicate device is the fastest pathway for Class II devices.

Question 50: The central principle of a Premarket Notification (510(k)) submission is demonstrating:

Substantial equivalence to a predicate device (Correct answer)
Probable benefit outweighs the risk of use
Cost-effectiveness compared to existing treatments
Novelty and innovation

Correct answer: Substantial equivalence to a predicate device

The core of a 510(k) submission is to demonstrate that the new device is 'substantially equivalent' to a legally marketed device (the predicate device) in terms of intended use, technological characteristics, and safety and effectiveness. This means the new device is at least as safe and effective as the predicate.

Question 51: Under the EU Medical Device Regulation (MDR 2017/745), which of the following is a primary objective of a Post-Market Clinical Follow-up (PMCF) plan?

To replace the need for pre-market clinical investigation data for high-risk devices.
To fulfill the reporting requirements for individual serious adverse events to competent authorities.
To gather marketing data and user preferences for the next product generation.
To proactively collect and evaluate clinical data to confirm the safety and performance of the device throughout its expected lifetime. (Correct answer)

Correct answer: To proactively collect and evaluate clinical data to confirm the safety and performance of the device throughout its expected lifetime.

The EU MDR, Annex XIV, Part B, defines Post-Market Clinical Follow-up (PMCF) as a continuous process to update the clinical evaluation. Its main purpose is to proactively gather clinical data on a CE-marked device to confirm its ongoing safety and performance and to ensure the continued acceptability of identified risks.

Question 52: Which GMP regulation governs Current Good Manufacturing Practice for finished pharmaceuticals in the US?

21 CFR Part 820
21 CFR Part 211 (Correct answer)
21 CFR Part 110
21 CFR Part 600

Correct answer: 21 CFR Part 211

21 CFR Part 211 establishes CGMP requirements for finished pharmaceutical products manufactured in the US.

Question 53: In a pediatric drug development program, what does a Pediatric Study Plan (PSP) require the sponsor to address?

The IND safety reporting schedule for all age groups
Adult Phase 3 trial design and statistical power calculations
The studies the sponsor plans to conduct in pediatric populations, relevant timelines, and justification for any waivers or deferrals (Correct answer)
Post-market surveillance commitments for adult populations

Correct answer: The studies the sponsor plans to conduct in pediatric populations, relevant timelines, and justification for any waivers or deferrals

A PSP outlines the sponsor's plan for studying the drug in relevant pediatric populations, including study designs, age groups, and justification for any requested waivers or deferrals under PREA.

Question 54: Which of the following is a key responsibility of management with respect to the Quality System, as outlined in 21 CFR 820 Subpart B?

Authoring every standard operating procedure (SOP) for the facility.
Reviewing and approving every individual complaint file.
Ensuring that the quality policy is established and that adequate resources are provided for the quality system. (Correct answer)
Personally performing all internal quality audits.

Correct answer: Ensuring that the quality policy is established and that adequate resources are provided for the quality system.

21 CFR 820.20, Management Responsibility, requires that executive management establish its policy and objectives for quality, and ensure the quality policy is understood, implemented, and maintained. Management is also responsible for providing adequate resources, including trained personnel, to implement and maintain the quality system. While they must review the suitability of the quality system, they are not required to perform all audits or approve every single record personally.

Question 55: Which element is most essential in a regulatory submission timeline when multiple global agencies are targeted?

Prioritizing the agency with the longest review time last
Identifying agency-specific requirements and building in time for translations and local data supplements (Correct answer)
Using a single project manager for all country submissions regardless of expertise
Submitting identical dossiers to all agencies on the same day

Correct answer: Identifying agency-specific requirements and building in time for translations and local data supplements

Global submissions require mapping agency-specific requirements, local data needs, and translation timelines to create a realistic multi-agency submission schedule.

Question 56: In a risk management context, how should new post-market safety information that reveals an unacceptable risk-benefit ratio be handled?

Immediately withdraw the device without regulatory notification
Issue a press release to notify the public directly
Feed it back into the risk management file and reassess risk controls (Correct answer)
Archive the information and await the next scheduled design review

Correct answer: Feed it back into the risk management file and reassess risk controls

ISO 14971 requires that post-production information be evaluated and, if it indicates an unacceptable risk, fed back into the risk management process to update controls.

Question 57: What role does regulatory intelligence play in strategic planning?

Prepares advertising slogans
Replaces submission documents
Informs proactive decision-making (Correct answer)
Eliminates need for marketing

Correct answer: Informs proactive decision-making

Regulatory intelligence involves systematically collecting, analyzing, and interpreting information about current and emerging regulatory requirements, guidelines, and trends worldwide. This intelligence allows companies to anticipate future regulatory challenges, adapt their development strategies, and make proactive decisions. It helps in navigating complex global regulatory landscapes and optimizing product development pathways.

Question 58: In adaptive clinical trial design, an interim analysis that allows sample size re-estimation based on unblinded effect size data is regulated under which FDA guidance framework?

ICH E6(R2)
FDA guidance on Adaptive Designs for Clinical Trials of Drugs and Biologics (2019) (Correct answer)
21 CFR Part 312.21
FDA guidance on Non-Inferiority Clinical Trials

Correct answer: FDA guidance on Adaptive Designs for Clinical Trials of Drugs and Biologics (2019)

FDA's 2019 adaptive design guidance addresses unblinded sample size re-estimation, response-adaptive randomization, and other adaptive elements.

Question 59: Which GCP principle requires that the benefit-to-risk ratio be favorable before a clinical trial begins?

Justice
Veracity
Beneficence and non-maleficence (Correct answer)
Autonomy

Correct answer: Beneficence and non-maleficence

Beneficence (do good) and non-maleficence (avoid harm) together require a favorable benefit-risk assessment prior to trial initiation.

Question 60: Which of the following scenarios represents a 'near miss' that should still be captured in the PMS system even though no injury occurred?

A device alarmed incorrectly but the clinician caught the error before patient harm (Correct answer)
A salesperson quoted an incorrect price to a hospital
A device was shipped to an incorrect warehouse address
A training video for the device contained a typographical error

Correct answer: A device alarmed incorrectly but the clinician caught the error before patient harm

Near-miss events where device performance could have caused harm are valuable PMS data because they signal potential failure modes requiring risk assessment.

Question 61: A company plans to launch its new pharmaceutical product in the United States and the European Union simultaneously. The most effective strategic regulatory planning would involve:

Preparing the US submission first and then adapting it for the EU several years later.
Developing a harmonized development plan that considers the requirements of both the FDA and EMA from the outset. (Correct answer)
Focusing exclusively on the requirements of the larger market and hoping it satisfies the other.
Submitting identical dossiers to both agencies without any country-specific modifications.

Correct answer: Developing a harmonized development plan that considers the requirements of both the FDA and EMA from the outset.

An effective global regulatory strategy involves integrating and harmonizing the requirements of different target regions from the beginning of product development. This proactive approach, often guided by ICH guidelines, helps streamline development, avoid redundant testing, and facilitate more efficient submissions. Simply adapting one region's dossier for another or submitting identical packages is often inefficient and can lead to significant delays or rejection, as specific local requirements would be missed.

Question 62: A medical device manufacturer is preparing labeling for a Class IIa sterile device to be marketed in the European Union. According to the Medical Device Regulation (EU 2017/745), which of the following must be affixed to the device label?

The full address of the European Competent Authority that reviewed the technical documentation.
The UL (Underwriters Laboratories) certification symbol.
The CE mark followed by the four-digit identification number of the Notified Body. (Correct answer)
The CE mark alone, without any additional numbers.

Correct answer: The CE mark followed by the four-digit identification number of the Notified Body.

Under the EU MDR, devices that require the involvement of a Notified Body for conformity assessment (including Class IIa, IIb, and III devices) must bear the CE mark followed by the Notified Body's unique four-digit identification number. This signifies that the Notified Body has reviewed and certified the manufacturer's conformity assessment. Class I devices that are not sterile or have no measuring function are self-certified and bear the CE mark alone.

Question 63: A manufacturer's EU Authorized Representative receives a serious incident report from a notified body. Under EU MDR Article 87, the manufacturer must report this to which entity?

The competent authority of the Member State where the incident occurred (Correct answer)
The European Commission directly
Their ISO certification body
The WHO global reporting database

Correct answer: The competent authority of the Member State where the incident occurred

Under EU MDR Article 87, serious incidents must be reported to the competent authority of the Member State where the incident took place.

Question 64: What is pharmacovigilance?

Post-approval testing
Monitoring drug safety after approval (Correct answer)
Advertising compliance
Marketing surveillance

Correct answer: Monitoring drug safety after approval

Pharmacovigilance is the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problem. It is a crucial post-marketing activity that involves continuously monitoring the safety of medicines once they are available to the public. This ongoing surveillance helps identify new or rare adverse reactions that may not have been detected during clinical trials.

Question 65: Which section of an NDA contains the proposed labeling, including prescribing information?

Module 1 — Administrative Information (Correct answer)
Module 3 — Quality
Module 5 — Clinical Study Reports
Module 2 — Summaries

Correct answer: Module 1 — Administrative Information

Module 1 of the CTD/NDA contains administrative and regional documents including proposed labeling and prescribing information.

Question 66: During the IND review period, what is the standard FDA review clock before a clinical trial may begin (absent a clinical hold)?

90 calendar days
60 calendar days
7 calendar days
30 calendar days (Correct answer)

Correct answer: 30 calendar days

FDA has 30 calendar days to review an IND; if no clinical hold is issued, the sponsor may proceed with the proposed investigation.

Question 67: A manufacturer becomes aware that its marketed medical device has malfunctioned. Although the event did not cause a death or serious injury, the manufacturer determines that if the malfunction were to recur, it would be likely to cause or contribute to a death or serious injury. Under US FDA regulations (21 CFR 803), how soon must the manufacturer report this event?

Within 10 working days
This event does not require a report
Within 30 calendar days (Correct answer)
Within 5 working days

Correct answer: Within 30 calendar days

According to 21 CFR 803.50(a)(2), a manufacturer must submit a Medical Device Report (MDR) no later than 30 calendar days after becoming aware of information that reasonably suggests a device has malfunctioned and would be likely to cause or contribute to a death or serious injury if the malfunction were to recur.

Question 68: Under FDA's Pediatric Research Equity Act (PREA), when must a sponsor submit a Pediatric Study Plan (PSP)?

At IND submission
With the NDA/BLA submission
No later than 60 days after an end-of-Phase II meeting (Correct answer)
Before initiating any Phase I trial

Correct answer: No later than 60 days after an end-of-Phase II meeting

PREA requires sponsors to submit an initial PSP (iPSP) no later than 60 days after the end-of-Phase II meeting with FDA.

Question 69: In the context of regulatory strategic planning, 'lifecycle management' refers to:

Managing employee careers within the regulatory department
Annual renewal of marketing authorizations
Planning regulatory activities from development through post-market to maximize product value (Correct answer)
The FDA's process for reviewing product changes over time

Correct answer: Planning regulatory activities from development through post-market to maximize product value

Regulatory lifecycle management encompasses all regulatory activities from initial development through post-approval changes, line extensions, and eventual product discontinuation.

Question 70: In a two-period crossover PK study, the primary concern with a short washout period is:

IRB non-compliance
Sequence imbalance
Carryover effect from the first treatment period (Correct answer)
Increased dropout rate

Correct answer: Carryover effect from the first treatment period

A carryover effect occurs when drug from period 1 is still present during period 2, confounding period 2 PK measurements.

Question 71: Under US MDR regulations, what is the consequence of a manufacturer failing to submit a required MDR within the mandated timeframe?

The device is automatically recalled by FDA
No regulatory consequence until a second violation occurs
FDA may issue a Warning Letter, initiate seizure, or pursue injunctive relief (Correct answer)
The manufacturer receives a minor administrative fine only

Correct answer: FDA may issue a Warning Letter, initiate seizure, or pursue injunctive relief

Failure to submit timely MDRs is a violation of 21 CFR Part 803 and can result in Warning Letters, injunctions, seizure actions, or civil money penalties.

Question 72: A pharmaceutical manufacturer receives an FDA Form 483 with three inspectional observations at the close-out of a GMP inspection. What is the most critical immediate action for the company?

Begin remediation but refrain from communicating with the FDA until all actions are complete.
Immediately file a formal dispute with the agency's legal counsel.
Wait for the official Establishment Inspection Report (EIR) before taking any action.
Submit a comprehensive written response within 15 business days outlining corrective and preventive actions (CAPAs). (Correct answer)

Correct answer: Submit a comprehensive written response within 15 business days outlining corrective and preventive actions (CAPAs).

The FDA expects a formal written response to a Form 483 within 15 business days. A timely and thorough response that acknowledges the observations and details the company's CAPA plan is crucial. This demonstrates a commitment to compliance and can help prevent the escalation of regulatory action, such as the issuance of a Warning Letter.

Question 73: What is the role of a Common Technical Document (CTD)?

To replace trial protocols
To track adverse events only
To outline marketing procedures
To harmonize regulatory submissions (Correct answer)

Correct answer: To harmonize regulatory submissions

The Common Technical Document (CTD) is an internationally agreed-upon format for organizing applications to regulatory authorities for the registration of medicines. Its primary role is to harmonize the structure and content of regulatory submissions across different regions, such as the US, Europe, and Japan. This standardization streamlines the review process and reduces the burden on pharmaceutical companies.

Question 74: Which element is NOT a required component of a pharmaceutical quality system under ICH Q10?

Corrective and preventive action system
Mandatory third-party audits (Correct answer)
Continual improvement of the process
Management responsibility

Correct answer: Mandatory third-party audits

ICH Q10 requires management responsibility, CAPA, and continual improvement, but does not mandate third-party audits as a required element.

Question 75: Which of the following statements BEST distinguishes the Premarket Approval (PMA) pathway from the 510(k) pathway?

The PMA pathway requires a demonstration of safety and effectiveness through clinical data, whereas a 510(k) relies on substantial equivalence to a predicate. (Correct answer)
510(k) submissions are only for Class I devices, while PMA submissions are for Class II and III devices.
The standard review timeline for a 510(k) is 180 days, whereas for a PMA it is 90 days.
A 510(k) results in an 'approval' letter, while a PMA results in a 'clearance' letter.

Correct answer: The PMA pathway requires a demonstration of safety and effectiveness through clinical data, whereas a 510(k) relies on substantial equivalence to a predicate.

The fundamental difference lies in the evidence required. The PMA process requires manufacturers to provide valid scientific evidence, typically including clinical trial data, to independently demonstrate a reasonable assurance of the device's safety and effectiveness. In contrast, the 510(k) pathway requires a demonstration of substantial equivalence to a legally marketed predicate device, leveraging the predicate's established safety and effectiveness profile.

Question 76: An internal audit at a medical device manufacturer reveals that three separate production batches failed final inspection for the same dimensional specification over the past two months. The issue was documented, and the non-conforming products were scrapped each time. According to 21 CFR 820.100, which of the following actions is now required?

Initiate a corrective action to investigate the root cause of the failures. (Correct answer)
Continue to monitor the trend at the next management review.
Retrain all production operators on the specific inspection procedure.
Issue a field correction for all distributed batches.

Correct answer: Initiate a corrective action to investigate the root cause of the failures.

The recurring nature of the non-conformance indicates a systemic issue that requires a formal Corrective and Preventive Action (CAPA) investigation to find and eliminate the root cause, as required by 21 CFR 820.100. Scrapping the product is a 'correction,' but it does not prevent recurrence. Retraining may be part of a corrective action, but it should not be implemented until a root cause is identified. A field correction is not indicated as the product was not distributed.

Question 77: What is the strategic advantage of using a pre-submission meeting (Type B meeting) with FDA during drug development?

It locks FDA into approving the submission without further review
It allows sponsors to align on study designs, endpoints, and data requirements before costly investments (Correct answer)
It substitutes for formal Phase 2 clinical trial requirements
It guarantees expedited review timelines post-submission

Correct answer: It allows sponsors to align on study designs, endpoints, and data requirements before costly investments

Type B meetings (including End-of-Phase 2 and pre-NDA meetings) allow sponsors to gain FDA feedback on development plans before committing resources, reducing submission risk.

Question 78: What is the significance of a 'retrospective validation' approach?

It validates a process before production begins
It uses historical production data to validate an established process (Correct answer)
It concurrently collects data during routine production
It validates analytical testing methods

Correct answer: It uses historical production data to validate an established process

Retrospective validation uses accumulated historical batch data to demonstrate that an existing process has been operating in a state of control.

Question 79: What is the primary regulatory concern addressed by 21 CFR Part 11?

Electronic records and electronic signatures (Correct answer)
Computer system validation protocols
Environmental controls in cleanrooms
Data backup and disaster recovery

Correct answer: Electronic records and electronic signatures

21 CFR Part 11 establishes criteria under which FDA considers electronic records and electronic signatures to be trustworthy and equivalent to paper records.

Question 80: In strategic planning for a generic drug, which factor most significantly determines the regulatory pathway in the US?

The manufacturing site's ISO certification status
The size of the patient population needing the drug
The brand drug's patent expiration date and market exclusivity status (Correct answer)
Whether the active ingredient has been approved in Europe

Correct answer: The brand drug's patent expiration date and market exclusivity status

Patent expiration and exclusivity periods (including 180-day exclusivity for first filers) are central to determining when and how a generic ANDA can be strategically filed.

Question 81: As part of due diligence for a potential company acquisition, a regulatory affairs manager is tasked with evaluating the target company's product portfolio. What is the MOST critical regulatory aspect to assess?

The number of employees in the target company's regulatory affairs department.
The aesthetic design of the product's packaging and labeling.
The compliance status of the products, including any outstanding regulatory actions or unresolved issues with health authorities. (Correct answer)
The marketing team's budget for post-launch promotional activities.

Correct answer: The compliance status of the products, including any outstanding regulatory actions or unresolved issues with health authorities.

During due diligence, the primary concern for a regulatory professional is to assess regulatory compliance and risk. This involves reviewing the product's approval history, inspection reports, any ongoing compliance issues (like warning letters), and the overall health of the regulatory filings. These factors can represent significant liabilities and impact the product's viability and the company's valuation. While department size and marketing budgets are relevant to the business, the core regulatory risk lies in the compliance status.

Question 82: A pharmaceutical manufacturer receives a batch of active pharmaceutical ingredient that fails identity testing. What is the required disposition?

Use under a deviation if potency is acceptable
Place in quarantine and notify the supplier only
Reject and return or destroy the material (Correct answer)
Retest using a different method before rejecting

Correct answer: Reject and return or destroy the material

Under 21 CFR 211.84, components failing identity testing must be rejected and cannot be used in drug product manufacturing.

Question 83: When developing a regulatory strategy, what is the primary purpose of pre-submission meetings and other formal interactions with health authorities?

To negotiate lower user fees for the marketing application review.
To gain clarity on regulatory expectations, obtain guidance on the development plan, and de-risk the submission process. (Correct answer)
To obtain a binding guarantee of product approval before submitting the formal application.
To receive informal, non-binding feedback from competitors about the development plan.

Correct answer: To gain clarity on regulatory expectations, obtain guidance on the development plan, and de-risk the submission process.

Formal interactions with health authorities, such as pre-submission meetings, are a critical component of regulatory strategy. Their main purpose is to allow sponsors to present their development plan and receive feedback, ask specific questions, and gain alignment on key issues before a formal marketing application is submitted. This proactive communication helps to identify and mitigate potential hurdles, clarify regulatory expectations, and ultimately reduce the risk of major delays or rejection during the review process.

Question 84: Which FDA guidance describes the expectation that manufacturers maintain a vigilance system to detect, report, and correct problems with marketed devices?

FDA Guidance on Q-Submissions
FDA Guidance on De Novo Classification
FDA Guidance on Predetermined Change Control Plans
FDA Guidance on Medical Device Reporting for Manufacturers (Correct answer)

Correct answer: FDA Guidance on Medical Device Reporting for Manufacturers

FDA's MDR guidance for manufacturers outlines the vigilance system expectations, including what constitutes a reportable event and required timelines.

Question 85: Under 21 CFR Part 312, a Type B meeting with FDA is most commonly used to discuss:

REMS program requirements after approval
Post-approval label changes
End-of-Phase 2 issues and pre-NDA/BLA discussions (Correct answer)
IND safety reporting procedures

Correct answer: End-of-Phase 2 issues and pre-NDA/BLA discussions

Type B meetings include End-of-Phase 1, End-of-Phase 2, pre-NDA/BLA, and pre-BLA meetings — they are milestone meetings that occur at defined stages of drug development.

Question 86: What is the significance of a Breakthrough Therapy designation granted by FDA?

It provides more intensive FDA guidance and organizational commitment to expedite development of a drug for serious conditions (Correct answer)
It waives all Phase 3 clinical trial requirements
It grants the product seven years of market exclusivity
It automatically grants marketing approval without further review

Correct answer: It provides more intensive FDA guidance and organizational commitment to expedite development of a drug for serious conditions

Breakthrough Therapy designation provides intensive FDA guidance, senior agency involvement, and rolling review to expedite development of drugs addressing serious unmet needs.

Question 87: What term describes the process by which an IRB reviews a study where the only involvement is a minimal-risk survey of adults?

Expedited review
Exempt determination (Correct answer)
Full board review
Waived consent review

Correct answer: Exempt determination

Research involving minimal risk with anonymous surveys of adults may qualify as exempt from IRB oversight under 45 CFR 46.104.

Question 88: What is an eCTD (electronic Common Technical Document)?

A paper-based submission format accepted by EU only
An EMA-only internal document management system
A type of clinical database used in trials
A standardized electronic format for submitting regulatory dossiers to health authorities (Correct answer)

Correct answer: A standardized electronic format for submitting regulatory dossiers to health authorities

The eCTD is the standard electronic format for organizing and submitting regulatory dossiers to authorities such as FDA, EMA, Health Canada, and PMDA.

Question 89: A manufacturer identifies through PMS that a device component is failing at a rate higher than predicted in the design phase. What is the MOST appropriate immediate next step?

Conduct a root cause analysis and assess whether a CAPA or field action is needed (Correct answer)
Continue selling the current inventory while redesigning the next version
Remove the device from the market without notifying competent authorities
Notify the FDA only after 30 days have passed

Correct answer: Conduct a root cause analysis and assess whether a CAPA or field action is needed

Discovering an unexpected failure rate requires root cause analysis and a CAPA assessment to determine if a field safety corrective action is necessary.

Question 90: For a pharmaceutical product manufactured and distributed in the United States, which document provides the complete, official manufacturing history of a finished batch, including all production and control records?

The Batch Production and Control Record (BPCR) (Correct answer)
The Drug Master File (DMF)
The Master Batch Record (MBR)
The Standard Operating Procedure (SOP)

Correct answer: The Batch Production and Control Record (BPCR)

Per 21 CFR 211.188, the Batch Production and Control Record (BPCR) is the comprehensive record containing all the data and history of the manufacture of a single batch. The Master Batch Record is the approved template or recipe. A Drug Master File is a submission to the FDA containing confidential information. An SOP is a general procedure, not a batch-specific record.

Question 91: Which of the following records serves as the comprehensive 'recipe' or set of instructions for manufacturing a specific medical device, containing all procedures and specifications for a finished device?

Design History File (DHF)
Quality System Record (QSR)
Device Master Record (DMR) (Correct answer)
Device History Record (DHR)

Correct answer: Device Master Record (DMR)

The Device Master Record (DMR), as defined in 21 CFR 820, is a compilation of records containing the procedures and specifications for a finished device. It includes device specifications, production process specifications, quality assurance procedures, and packaging and labeling specifications. The DHF describes the design history, and the DHR provides evidence that a specific batch was made according to the DMR.

Question 92: A regulatory professional must communicate an unexpected trial failure to multiple stakeholders including R&D, finance, and commercial teams. Which communication strategy is MOST effective?

Issue a press release first to ensure all internal groups receive the same message
Share information only with R&D until a recovery plan is established
Send a single detailed technical report to all groups simultaneously
Tailor separate briefings to each audience's specific concerns and decision needs, keeping a consistent core message (Correct answer)

Correct answer: Tailor separate briefings to each audience's specific concerns and decision needs, keeping a consistent core message

Tailoring messages to each audience's perspective while maintaining a consistent factual core ensures each stakeholder group can process the information and make appropriate decisions.

Question 93: A pharmaceutical company becomes aware of new data confirming a causal link between its marketed drug and a previously unknown serious adverse reaction. To update the Prescribing Information to add a new warning, which is the MOST appropriate regulatory submission to the FDA?

A New Drug Application (NDA).
An annual report.
A Prior Approval Supplement (PAS).
A "Changes Being Effected" (CBE-0) supplement. (Correct answer)

Correct answer: A "Changes Being Effected" (CBE-0) supplement.

For critical safety-related labeling changes, such as adding or strengthening a contraindication, warning, precaution, or adverse reaction, regulations permit the submission of a "Changes Being Effected" (CBE-0) supplement. This allows the applicant to implement the change immediately upon the FDA's receipt of the supplement, ensuring rapid communication of important safety information. A PAS would require FDA approval before implementation, causing a delay.

Question 94: Which element is MANDATORY in a PMS plan according to EU MDR Annex III?

A proactive and systematic procedure to collect and review post-market experience (Correct answer)
A marketing communication plan for healthcare providers
A schedule of notified body surveillance audits
A list of countries where the device is not yet marketed

Correct answer: A proactive and systematic procedure to collect and review post-market experience

EU MDR Annex III requires the PMS plan to specify a proactive, systematic procedure for gathering and reviewing post-market experience from clinical and non-clinical sources.

Question 95: Which concept does ICH Q9 Quality Risk Management introduce as a foundation for risk-based decision-making?

Continual process verification
Design space and proven acceptable ranges
Risk assessment, risk control, and risk review (Correct answer)
Quality by design principles

Correct answer: Risk assessment, risk control, and risk review

ICH Q9 establishes risk assessment, risk control, and risk review as the core elements of a structured quality risk management process.

Question 96: Under 21 CFR 211.68, computerized systems used in drug manufacturing must have what safeguard?

Dual-factor authentication for all users
Encryption of all stored data
Input/output verification to ensure accuracy (Correct answer)
Quarterly system revalidation

Correct answer: Input/output verification to ensure accuracy

21 CFR 211.68 requires that input to and output from computerized systems be checked for accuracy to prevent data integrity failures.

Question 97: Which internal department is most often engaged during regulatory planning?

Logistics
Finance
Human Resources
Clinical and R&D teams (Correct answer)

Correct answer: Clinical and R&D teams

During regulatory planning, the regulatory affairs department works most closely with clinical and R&D teams because these departments generate the scientific data required for regulatory submissions. Regulatory professionals guide these teams on study design, data collection, and documentation to ensure compliance with regulatory standards. This collaboration is essential for developing a robust regulatory strategy and preparing comprehensive dossiers.

Question 98: Under GCP (ICH E6(R2)), who holds primary responsibility for the conduct of a clinical trial at an investigational site?

The IRB/IEC
The principal investigator (Correct answer)
The sponsor's monitor
The contract research organization (CRO)

Correct answer: The principal investigator

ICH E6(R2) assigns primary responsibility for the conduct of the trial at a site to the principal investigator (PI).

Question 99: What is the Hatch-Waxman Act's primary contribution to generic drug development in the US?

It created the Orphan Drug Act incentives for rare disease products
It mandated electronic submissions for all NDAs and ANDAs
It required biosimilar applicants to conduct head-to-head comparative clinical trials
It established the ANDA pathway allowing generics to rely on the innovator's safety and efficacy data while demonstrating bioequivalence (Correct answer)

Correct answer: It established the ANDA pathway allowing generics to rely on the innovator's safety and efficacy data while demonstrating bioequivalence

The Hatch-Waxman Act (1984) created the abbreviated pathway (ANDA) that allows generic manufacturers to rely on the RLD's existing safety/efficacy data by demonstrating bioequivalence.

Question 100: What is a Class I recall?

Potentially serious health risk (Correct answer)
Technical specification update
Cosmetic labeling issue
Voluntary return for review

Correct answer: Potentially serious health risk

A Class I recall is the most serious type of recall issued by the FDA, indicating that there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death. These recalls are initiated when a product poses a significant and immediate threat to public health. They require immediate action to remove the product from the market.

RAC Regulatory Affairs Certification Exam

The RAC exam, administered by RAPS, certifies regulatory affairs professionals in their knowledge of strategic planning, pre-marketing, post-marketing, and interfacing with regulatory authorities for drugs and devices.

100

Questions

120 min

Time Limit

75%

To Pass

Checking for saved progress...

Exam Rules

You can skip questions and return to them later
Flag questions for review before submitting
No feedback shown until you submit the entire exam
Unanswered questions count as wrong — answer everything
10 pretest questions are mixed in and don't affect your score
Timer auto-submits when time runs out
Your progress is auto-saved every 30 seconds

These practice questions were written with AI tools. They are not real exam questions. We have not yet matched this exam's facts to an official source, so confirm fees, dates and rules with the exam body. Not reviewed by a subject-matter expert. Editorial policy